Evoke Pharma's (EVOK) shares soar 29% after a Phase IIb study shows that the company's intranasal delivery of metoclopramide is better at managing the symptoms of diabetic gastroparesis compared with the pill version.
Evoke plans to start a Phase III trial soon.
No new treatments for managing the symptoms of gastroparesis have received FDA approval since 1980. "There are very few drugs in clinical development for this debilitating diabetic complication," says Evoke CEO Dave Gonyer. (PR)